CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

LifeStance Health Q3 revenue beats on clinician growth, lifts FY outlook

By Reuters News


Overview

  • US outpatient mental healthcare provider's Q3 revenue rose 25%, beating analyst expectations

  • Q3 adjusted EBITDA rose 70%, beating analyst expectations

  • Company raised full-year 2026 revenue and adjusted EBITDA guidance


Outlook

  • Company raises 2026 revenue outlook to $1.741 bln-$1.761 bln

  • Company now sees 2026 adj EBITDA at $242 mln-$250 mln

  • Company expects Q4 revenue of $446 mln-$466 mln


Result Drivers

  • VISIT VOLUME AND CLINICIAN GROWTH - Co said revenue growth was driven primarily by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit

  • OPERATING LEVERAGE - Co said adjusted EBITDA margin increased due to higher revenue per visit, lower center costs as a percentage of revenue, and improved operating leverage from revenue growing faster than general and administrative expenses


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$455.90 mln

$431.82 mln (9 Analysts)

Q3 Net Income

$22.40 mln

Q3 Adjusted EBITDA

Beat

$68.40 mln

$55.31 mln (9 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy"

  • Wall Street's median 12-month price target for LifeStance Health Group, Inc. is $15.00, about 5.6% above its November 4 closing price of $14.21

  • The stock recently traded at 65 times the next 12-month earnings vs. a P/E of 51 three months ago


Reuters Recommended Reads

  • Nov 4 - Acadia Healthcare Q3 revenue beats estimates; 2026 outlook raised

  • Nov 4 - Ardent Health Q3 revenue beats analyst estimates

  • Nov 4 - Health insurers, hospitals rally after sweeping midterm win for Democrats


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.